

STOCK RECOMMENDATION - JANUARY 16TH, 2023

MARKET REVIEW

For the week ended January 13th, 2023.

- The Nigerian equities market closed the trading week on a positive note, as the All-Share Index gained 2.52% WoW to close at 52,512.48pts. The Year-to-Date return improved to 2.46% (from -0.06% in the prior week).
- Also, performance across the sectoral indices was largely positive as all sectoral indices closed positive except the NGXINS (-1.64% WoW)
- THOMASWY emerged as the week's top gainer (+52.58% WoW), while CHELLARAM (-33.66% WoW) was the week's top loser. FBNH and BUACEMENT topped the activities' charts as the most traded stocks by volume and value, respectively.

MARKET PREVIEW

For the week commencing January 16th, 2023.

- We expect a stay of the positive sentiment in the equities market this week as the market appears to still be in the bullish frenzy it closed the previous year with.
- Moreso, the persistent decline in average T-bills yield might be a push factor for improved participation in the equities market. On the other hand, the forthcoming inflation report due to be released this week, is expected to have minimal influence on the performance of the equities market.
- However, we do not rule out the possibility of profit taking on tickers that have gained considerably in the past weeks.
- Overall, we expect the market to record a positive outing this week.

THE WEEK THAT WAS (A REVIEW)

			Cur. Week	Prev. Week
NGXASI			52,512.48	51,222.34
Market Cap [NGN'trn]			28.60	27.90
Market Cap [USD 'bn]			61.95	60.43
Volume Traded [bn]			1.25	0.71
Value Traded [NGN'bn]			29.23	24.58
	NSEASI & Sect	toral Indices [Return Profile]		
	WtD	MtD	QtD	YtD
NGXASI	2.52%	2.46%	2.46%	2.46%
NGX-30	2.77%	2.88%	2.88%	2.88%
NGX-B10	3.48%	7.91%	7.91%	7.91%
NGX-FB10	0.68%	7.16%	7.16%	7.16%
NGX-OG5	3.19%	3.25%	3.25%	3.25%
NGX-INS10	-1.64%	1.00%	1.00%	1.00%
NGX-IND	3.34%	2.75%	2.75%	2.75%
Value (NGN)		Volume		
BUACEMENT	7,046,878,738	FBNH		300,948,544
AIRTELAFRI	6,229,488,380	STERLNBA	NK	116,700,841
FBNH	3,372,711,328	GTCO		90,203,029
GTCO	2,168,172,175	ZENITHBA	NK	74,852,121
MTNN	1,917,159,158	BUACEME		73,441,702
Highest Gainers	%	Highest Los	ers	%
THOMASWY	52.58%	CHELLARAN	Λ	-33.66%
CHAMS	17.39%	ROYALEX		-10.78%
ABCTRANS	16.00%	ABBEYBDS		-10.00%
LIVESTOCK	15.04%	NEM		-10.00%
MBENEFIT	14.29%	CORNERST		-8.33%



	Fundamentals					Trailing					arket Perfor	mance	Valuation						
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2023 TP	Last Wk. Pr	UPP	RT	
Financial Services																			
Banks																			
ACCESSCORP	0.09	15%	17%	1%	13.00	4.93	29.11	1.89x	0.32x	9.30	8.75	+9.41%	1.63	6.41	10.46	9.30	+12%	BUY	
ETI	0.09	16%	21%	1%	14.81	6.50	30.80	1.85x	0.39x	12.00	10.60	+13.21%	2.22	6.38	14.14	12.00	+18%	BUY	
FCMB	0.09	11%	11%	1%	11.14	1.52	13.31	2.60x	0.30x	3.95	3.51	+2.60%	2.60	1.64	4.26	3.95	+8%	HOLD	
FIDELITYBK	0.08	12%	12%	1%	11.91	1.34	11.01	3.79x	0.46x	5.10	4.36	+17.24%	2.51	2.23	5.61	5.10	+10%	HOLD	
FBNH	0.09	23%	23%	2%	11.03	5.62	24.89	2.07x	0.47x	11.60	11.00	+6.42%	3.89	3.62	14.08	11.60	+21%	BUY	
GTCO	0.08	37%	20%	3%	6.66	5.97	29.66	4.10x	0.83x	24.50	23.25	+6.52%	3.81	6.69	25.51	24.50	+4%	HOLD	
STANBIC	0.09	27%	19%	2%	7.76	5.57	29.34	5.74x	1.09x	33.45	32.00	-4.33%	6.72	5.75	38.67	32.00	+21%	BUY	
STERLNBANK	0.09	11%	12%	1%	12.15	0.61	5.19	2.56x	0.30x	1.55	1.40	+10.71%	2.62	0.58	1.53	1.55	-2%	HOLD	
UBA	0.09	17%	16%	1%	10.76	3.80	24.15	2.19x	0.35x	8.35	7.95	+9.87%	1.91	4.93	9.43	8.35	+13%	BUY	
UBN	0.08	10%	7%	1%	9.06	0.67	9.63	9.63x	0.67x	6.95	6.35	+0.78%	9.13	0.75	6.84	6.45	+6%	HOLD	
WEMABANK	0.09	9%	15%	1%	18.37	0.28	1.88	13.67x	2.05x	3.90	3.58	-1.28%	4.22	0.84	3.55	3.85	-8%	HOLD	
ZENITHBANK	0.07	35%	20%	3%	7.95	8.23	40.52	3.11x	0.63x	25.55	24.00	+6.46%	3.07	8.68	26.69	25.55	+4%	HOLD	
Insurance																			
AIICO	0.30	10%	20%	3%	6.44	0.24	1.17	2.67x	0.54x	0.64	0.60	+6.78%	3.00	0.22	0.66	0.63	+5%	HOLD	
LASACO	0.51	1%	1%	0%	2.19	0.05	6.33	21.94x	0.16x	1.10	0.89	+13.79%	8.45	0.14	1.16	0.99	+17%	BUY	
MANSARD	0.65	2%	6%	2%	3.76	0.09	1.57	21.94x	1.28x	2.14	2.00	0.00%	6.05	0.44	2.66	2.00	+33%	BUY	
NEM	0.73	19%	25%	14%	1.77	0.63	2.57	6.43x	1.58x	4.50	4.05	-10.00%	5.00	0.96	4.80	4.05	+19%	BUY	
WAPIC	0.40	-7%	-6%	-3%	2.13	-0.05	0.86	-7.98x	0.49x	0.45	0.41	+5.00%	0.50	0.82	0.41	0.42	-2%	HOLD	
CORNERST	0.39	16%	15%	6%	2.29	0.16	1.12	3.37x	0.49x	0.60	0.55	-8.33%	3.68	0.17	0.61	0.55	+11%	BUY	
CUSTODIAN	0.47	11%	16%	5%	3.03	1.85	11.46	3.21x	0.52x	6.00	5.90	0.00%	4.21	1.87	7.87	5.95	+32%	BUY	

www.meristemng.com

MERÍSTEM

	Fundamentals					Trailing				Market Performance				Valuation				
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2023 TP	Last Wk. Pr	UPP	RT
Other Financial Services																		
UCAP	0.04	61%	49%	2%	20.05	2.17	4.42	6.85x	3.36x	15.00	14.00	+6.07%	6.00	2.73	16.39	14.85	+10%	BUY
AFRIPRUD	0.20	39%	18%	8%	2.22	0.79	4.52	7.81x	1.37x	6.20	5.90	+3.33%	8.50	0.96	8.12	6.20	+31%	BUY
Consumer Staples & Discretionary																		
Breweries																		
GUINNESS	0.96	7%	15%	7%	2.37	6.55	42.43	10.57x	1.63x	69.30	69.30	0.00%	10.88	7.60	82.68	69.30	+19%	BUY
NB	0.94	4%	10%	3%	3.02	2.34	22.43	20.11x	2.10x	47.95	41.00	+14.63%	18.15	2.91	52.82	47.00	+12%	BUY
INTBREW	0.52	-3%	-5%	-2%	3.06	-0.24	5.06	-20.78x	0.99x	5.05	4.65	+6.38%	-	-	-	5.00	-	UR
Packaged Foods & Meats																		
BUAFOODS	0.61	21%	39%	13%	3.05	74.62	192.97	1.00x	0.39x	74.50	71.50	+14.62%	12.29	4.39	53.95	74.50	-28%	SELL
CADBURY	0.95	4%	15%	4%	3.72	1.28	8.26	9.46x	1.47x	12.25	11.90	+1.68%	8.85	1.57	13.86	12.10	+15%	BUY
DANGSUGAR	0.78	9%	22%	7%	3.35	2.58	11.63	6.66x	1.48x	17.20	16.00	+7.17%	6.76	2.56	17.31	17.20	+1%	HOLD
HONYFLOUR	0.90	-6%	-18%	-5%	3.29	-1.10	6.19	-2.20x	0.39x	2.43	2.20	+2.99%			-	2.41	-	UR
FLOURMILL	1.46	2%	11%	2%	4.74	5.09	47.82	5.89x	0.63x	30.00	28.40	+5.63%	7.12	5.71	40.68	30.00	+36%	BUY
NASCON	0.89	7%	21%	6%	3.35	1.30	6.21	8.09x	1.69x	11.10	10.50	-5.41%	8.90	1.48	13.17	10.50	+25%	BUY
NESTLE	1.13	11%	113%	12%	9.10	58.80	52.07	18.37x	20.74x	1,100.00	1,080.00	-1.82%	23.68	64.26	1,521.84	1,080.00	+41%	BUY
UACN	1.01	0%	0%	0%	2.22	0.00	16.75	2289.02x	0.62x	10.75	10.10	+0.98%	14.59	0.75	10.96	10.35	+6%	HOLD
UNILEVER	0.72	-4%	-5%	-3%	1.84	-0.59	11.28	-19.21x	1.01x	11.60	11.40	-1.72%	38.02	0.33	12.46	11.40	+9%	HOLD
Agricultural Products																		
OKOMUOIL	0.78	38%	56%	29%	1.93	22.37	39.62	7.38x	4.16x	165.00	165.00	0.00%	9.40	20.42	191.95	165.00	+16%	BUY
PRESCO	0.51	32%	59%	16%	3.67	23.05	39.06	5.97x	3.52x	137.50	137.50	0.00%	7.22	23.87	172.34	137.50	+25%	BUY
Household & Personal Products																		
PZ	0.70	3%	7%	2%	3.23	0.70	9.83	15.13x	1.07x	12.10	10.00	-7.05%	-	-	-	10.55	-	UR
VITAFOAM	1.29	11%	32%	14%	2.34	3.94	12.36	5.38x	1.72x	21.20	20.45	+3.67%	-	-	-	21.20	-	UR

www.meristemng.com

MERÍSTEM

Equity | Stock Recommendation

	Fundamentals				Trailing				Market Performance				Valuation					
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2023 TP	Last Wk. Pr	UPP	RT
Healthcare																	_	
Pharmaceuticals																		
MAYBAKER	0.77	11%	20%	9%	2.25	0.92	4.73	4.82x	0.94x	4.45	4.30	+3.49%	6.21	0.81	5.03	4.45	+13%	BUY
FIDSON	0.95	12%	30%	11%	2.63	2.11	7.04	4.43x	1.33x	9.79	9.34	+3.78%	4.34	3.62	15.70	9.34	+68%	BUY
GLAXOSMITH	0.92	4%	11%	4%	3.10	0.85	7.73	7.62x	0.84x	6.50	6.15	+5.69%	7.94	1.02	8.10	6.50	+25%	BUY
NEIMETH	0.42	-4%	-10%	-2%	5.87	-0.06	0.58	-27.03x	2.71x	1.56	1.43	+9.09%	2.35	0.85	2.00	1.56	+28%	BUY
Materials																		
Construction Materials																		
BUACEMENT*	0.43	29%	26%	13%	2.04	2.90	11.34	34.30x	8.77x	99.45	96.00	+1.74%	18.19	4.35	76.13	99.45	-23%	SELL
DANGCEM*	0.66	19%	36%	13%	2.78	17.56	49.19	15.37x	5.49x	270.00	261.00	+3.45%	6.83	43.80	299.15	270.00	+11%	BUY
WAPCO*	0.61	16%	14%	10%	1.42	3.45	24.82	7.34x	1.02x	25.30	24.00	+5.42%	5.60	6.46	38.65	25.30	+53%	BUY
Specialty Chemicals																-		
САР	1.43	11%	37%	15%	2.40	2.48	6.76	7.17x	2.63x	17.80	17.80	0.00%	9.49	2.02	19.19	17.80	+8%	HOLD
BERGER	1.14	3%	6%	4%	1.60	0.64	11.31	10.28x	0.58x	6.60	6.00	+10.00%	11.15	0.66	7.30	6.60	+11%	BUY
Energy																		
CONOIL	2.02	4%	18%	8%	2.33	6.38	35.63	4.16x	0.74x	26.50	26.50	0.00%	5.00	5.19	25.95	26.50	-2%	HOLD
ETERNA	2.07	0%	-1%	0%	4.03	-0.06	10.39	-116.36x	0.68x	7.20	6.65	+4.93%	8.05	0.73	5.88	7.02	-16%	SELL
ARDOVA	1.63	-2%	-29%	-3%	10.96	-2.86	9.82	-6.67x	1.95x	19.10	18.00	+3.80%	22.84	0.68	15.58	19.10	-18%	SELL
MRS	2.39	1%	6%	3%	2.04	3.56	58.95	3.96x	0.24x	14.10	14.10	0.00%	4.57	3.52	16.11	14.10	+14%	BUY
SEPLAT	0.26	18%	9%	5%	1.92	113.67	1,244.81	9.68x	0.88x	1,100.00	1,100.00	0.00%	8.87	134.32	1,191.42	1,100.00	+8%	HOLD
TOTAL	1.39	4%	33%	5%	6.54	47.08	141.49	4.51x	1.50x	212.30	193.00	+10.00%	5.07	46.90	237.70	212.30	+12%	BUY
Telecommunications																		
MTNN	0.79	18%	142.68%	14.37%	9.93	17.07	11.96	13.47x	19.22x	229.90	215.00	+6.93%	12.00	25.12	301.42	229.90	+31%	BUY
AIRTELAFRI*	0.38	11%	12%	4%	2.88	49.50	402.93	31.32x	3.85x	1,635.00	1,500.00	-5.20%	4.66	317.84	1,481.13	1,550.00	-4%	HOLD
	••••••								••••									



BVP= Book Value Per Share
P/E=Price-to-Earnings
AT=Asset Turnover
OM=Operating Margin
NM= Net Margin
ROA=Return on Asset
Lev=Leverage
UR=Under Review

Data in the Fundamental columns are based on trailing performance.

www.meristemng.com

Disclosure and Analyst certification on page 6



Analyst's Certification and Disclaimer

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

(1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and

(2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.

(3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

Investment Ratings

Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

Target Price Estimate

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

Ratings Specification

- BUY: Target Price of the stock is above the current market price by at least 10 percent
- HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.
- SELL: Target Price of the stock is more than **10 percent** below the current market price.

Definitions

Price Targets: Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

Asset allocation: The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

www.meristemng.com

Page | 6

Disclosure and Analyst certification on page 5



Conflict of Interest

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

Important Disclosure

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Meristem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, **the** company through its subsidiaries carries out stock broking, wealth management, trustees and registrars' businesses which are regulated by the SEC and ICMR.

IMPORTANT INFORMATION: DISCLAIMER

Meristem Securities Limited ("Meristem") equity reports and its attendant recommendations are prepared based on publicly available information and are meant for general information purposes only and it may not be reproduced or distributed to any other person. All reasonable care has been taken to ensure that the information contained herein is not misleading or untrue at the time of publication; **Meristem** can neither guarantee its accuracy nor completeness as they are an expression of our analysts' views and opinions.

Meristem and any of its associated or subsidiary companies or the employees thereof cannot be held responsible for any loss suffered by relying on the said information as this information as earlier stated, is based on publicly available information, analysts' estimates and opinions, and is meant for general information purposes and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell securities or any financial instruments. The value of any investment is subject to fluctuations, i.e., may fall and rise. Past performance is no guide to the future. The rate of exchange between currencies may cause the value of investment to increase or diminish. Hence investors may not get back the full value of their original investment.

Meristem Securities is registered with the Securities and Exchange (SEC) and is also a member of The Nigerian Stock Exchange (The NSE). Meristem Securities' registered office is at 20A Gerard Road, Ikoyi, Lagos, Nigeria. Website: www.meristemng.com; Email: research@meristemng.com. © Meristem Securities Limited 2023.



Contact Information

Brokerage and Retail Services

	Brokerage and Retail Services	
	topeoludimu@meristemng.com	(+234 905 569 0627)
	adaezeonyemachi@meristemng.com	(+234 808 369 0213)
	contact@meristemng.com	
	Investment Banking/Corporate	Finance
	rasakisalawu@meristemng.com	(+234 806 022 9889)
	seunlijofi@meristemng.com	(+234 808 536 5766)
	Wealth Management	
	funmilolaadekola-daramola@meristemng.com	(+234 805 498 4522)
	crmwealth@meristemng.com	(+234 01 738 9948)
	Registrars	
	oluseyiowoturo@meristemregistrars.com	(+234 802 321 0561)
	martinaosague@meristemregistrars.com	(+234 802 303 1783)
	www.meristemregistrars.com	
	Tel: +23401-280 9250	
_	Trust Services	
	damilolahassan@meristemng.com	(+234 803 613 9123)
	trustees@meristemng.com	
	Group Business Development	
	saheedbashir@mersitemng.com	(+234 802 454 6575)
	ifeomaanyanwu@meristemng.com	(+234 802 394 2967)
	info@meristemng.com	
	Meristem Finance	
	olasokomubo@meristemfinance.com	(+234 803 324 7996)
	mattheawotunde@meristemfinance.com	(+234 802 390 6249)
	Client Services	
	adefemitaiwo@meristemng.com	(+234 803 694 3034)
	car@meristemng.com	
	Investment Research	
	damilareojo@meristemng.com	(+234 816 890 2771)
	praiseihansekhien@meristemng.com	(+234 817 007 1512)
	research@meristemng.com	
Corporate websites:	www.meristemng.com www.meristemweal	Ith.com www.meristemregistrars.com
	a slop ha second on the fallowing alotherman	

Meristem Research can also be accessed on the following platforms: Meristem Research portal: research.meristemng.com

Bloomberg: MERI <GO>

Capital IQ: www.capitaliq.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG

Reuters: www.thomsonreuters.com

Page | 8

FactSet: www.factset.com

www.meristemng.com

Disclosure and Analyst certification on page 5